Eli Lilly (NYSE:LLY) reported positive results from an open-label study of its drug Omvoh in the treatment of moderately to severely active Crohn's disease. The study, called VIVID-2, showed that the ...

INDIANAPOLIS - Eli Lilly and Company (NYSE: NYSE:LLY), a pharmaceutical giant with a market capitalization of $783.7 billion ...

Mirikizumab showed superior maintenance efficacy over most treatments for ulcerative colitis (UC), according to a network ...

The management of bone metastases in endocrine-related cancers is a continually evolving field, marked by significant challenges and advances that affect ...

Researchers identified that the dominant B cell epitope of Lachnospiraceae flagellins and the utilization of the flagellin ...

Pyoderma gangrenosum and metastatic Crohn's disease can resemble the ulcerative phase of PAN. Other connective tissue diseases such as systemic lupus erythematosus, rheumatoid arthritis ...

Crohn’s disease can cause anal fistulas, which are tunnels that go from your anus to the surface of the skin around your anus. They usually begin as an infection in one of your anal glands and ...

Crohn's disease is a chronic inflammatory bowel disease that primarily affects the gastrointestinal tract but can affect other organs in the body too. Crohn's disease symptoms that involve ...

Approval was based on results of the VIVID-1 study, which found that Omvoh demonstrated significant clinical remission and endoscopic response rates in patients with Crohn disease. The FDA has ...

Jan. 16, 2025 – The FDA has approved the drug Omvoh for treating adults with moderately to severely active Crohn's disease, a type of chronic inflammatory bowel disease. This marks the second ...

Niktimvo marks the first FDA-approved therapy targeting CSF-1R to address inflammation and fibrosis in chronic graft-versus-host disease. The FDA has approved Incyte’s and Syndax’s Niktimvo ...